Magrolimab is named as an intervention in 2 current clinical trials in our Japan register. None are recruiting at the moment. All registered phases are Phase 1. The lead sponsor is Ono Pharmaceutical Co., Ltd. The most-studied condition is Metastatic Pancreatic Cancer.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
An Open-label, Uncontrolled Study of ONO-7913 and ONO-4538 in Combination With Modified FOLFIRINOX Therapy, the Standard of Care, as First-line Treatment in Patients With Metastatic Pancreatic Cancer
NCT06532344 · ClinicalTrials.gov ↗ · Metastatic Pancreatic Cancer
|
Phase 1 | Active, closed | Ono Pharmaceutical Co., Ltd | Japan |
|
The Study of ONO-7913, ONO-4538 and the Standard of Care as First-line Treatment in Patients Colorectal Cancer
NCT06540261 · ClinicalTrials.gov ↗ · Unresectable Colorectal Cancer
|
Phase 1 | Active, closed | Ono Pharmaceutical Co., Ltd | Japan |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Ono Pharmaceutical Co., Ltd | 2 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in Japan | 2 | 0 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our Japan register name Magrolimab (also registered as ONO-7913) as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Not at the moment. None of the 2 trials in our registers is recruiting; they are active but closed to enrolment, not yet open, or enrolling by invitation. Only the study team can confirm whether a patient is eligible.
The lead sponsor is Ono Pharmaceutical Co., Ltd. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Magrolimab works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Magrolimab works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Magrolimab (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.